Plain-English translation of NCT05962242 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new approach to treating HPV-positive oropharyngeal cancer (cancer of the throat) using lower doses of radiation therapy than are normally given. Researchers believe that lower radiation doses may work just as well as standard doses while causing fewer unpleasant side effects, especially when combined with chemotherapy. Your treatment plan will be personalized based on how your cancer responds to radiation, which will be monitored using a special blood test called NavDx.
Standard radiation therapy for head and neck cancer can cause significant side effects and damage to healthy tissue in the neck and throat area. Recent research suggests that lower radiation doses may be just as effective at preventing cancer from coming back, which means patients could have better quality of life during and after treatment.
You likely qualify if…
You likely don't qualify if…
You will receive radiation therapy in two or more phases over several weeks, with lower doses delivered to a smaller area than standard treatment. Your cancer's response will be monitored with blood tests (NavDx) during treatment, and your radiation plan may be adjusted based on those results—if your cancer responds quickly, you may receive less total radiation, but if it responds more slowly, you may receive an additional boost. You will also complete surveys about your overall health and wellbeing throughout the study.
AI-generated summary from trial data · Jun 16, 2026 · Not medical advice
United States